Erasca faces class action lawsuit
Analysis based on 6 articles · First reported Jun 12, 2026 · Last updated Jun 12, 2026
The class action lawsuit and the disclosures of patent infringement allegations and a patient death in clinical trials have severely impacted Erasca's stock price, causing significant declines. This event creates uncertainty for investors in the biotechnology sector, particularly those invested in companies with drug candidates in early development stages.
A class action lawsuit has been filed against Erasca, Inc. by Kirby McInerney LLP on behalf of investors who acquired Erasca securities between January 14, 2025, and April 26, 2026. The lawsuit alleges that Erasca, its CEO, and CFO made false and misleading statements about its oncology drug candidate, ERAS-0015. Specifically, Erasca allegedly presented ERAS-0015 as 'best-in-class' with superior preclinical results compared to Revolution Medicines' RMC-6236, without disclosing that these comparisons were improper, potentially leading to patent and trade secret disputes. On April 27, 2026, Erasca disclosed receiving a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015. On the same day, Erasca reported preliminary Phase 1 clinical data for ERAS-0015, including the death of a patient. These disclosures led to an 11% and then a 48% decline in Erasca's share price.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard